CERC - Cerecor Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
4.8700
-0.0100 (-0.20%)
As of 12:04PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close4.8800
Open4.9900
Bid4.8800 x 2200
Ask4.9300 x 1100
Day's Range4.8100 - 4.9900
52 Week Range2.7100 - 7.6500
Volume71,079
Avg. Volume101,095
Market Cap208.369M
Beta (3Y Monthly)2.15
PE Ratio (TTM)N/A
EPS (TTM)-1.1640
Earnings DateAug 7, 2019 - Aug 12, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est9.67
Trade prices are not sourced from all markets
  • GlobeNewswire14 days ago

    Cerecor Appoints Keith Schmidt to its Board of Directors

    Cerecor Inc. (CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare and orphan diseases in pediatrics and neurology, today announced the appointment of Keith Schmidt to its Board of Directors effective immediately.  Mr. Schmidt joins the Cerecor Board as a member of the Audit Committee, the Compensation Committee, and an independent director serving a term ending at the 2019 Annual Meeting.

  • GlobeNewswire15 days ago

    Cerecor Set to Join Russell 3000® Index

    Cerecor Inc. (CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare and orphan diseases in pediatrics and neurology, today announced that it is set to join the Russell 3000® Index at the conclusion of the 2019 Russell indexes annual reconstitution, effective after the U.S. market opens on July 1, 2019, according to a preliminary list of additions posted June 7, 2019. Membership in the Russell 3000® Index, which remains in place for one year, means the automatic inclusion of Cerecor’s common stock in index funds designed to track stocks included in the Russell 3000® Index. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings and style attributes.

  • Zacks Small Cap Researchlast month

    CERC: Completion of Phase 1 Trial of CERC-801…

    On April 29, 2019, Cerecor Inc. (CERC) announced dosing has completed in the Phase 1 clinical trial of CERC-801 (D-galactose), which is being developed for the treatment of Phosphoglucomutase 1 (PGM1) deficiency. The open label, randomized, single dose, 4-way crossover study in 16 healthy adult volunteers showed CERC-801 to be safe and well tolerated with no reports of serious adverse events. The company has also initiated a natural history study to collect efficacy and safety data from CDG patients treated with monosaccharide replacement therapy, which will be an important part of the application for approval using the 505(b)(2) pathway.

  • GlobeNewswire2 months ago

    Cerecor Reports First Quarter 2019 Results

    - Positive interim results from the Phase l study of CERC-301 in nOH -Positive results from Phase I Safety Data for CERC-801 in Healthy Volunteers ROCKVILLE, Md., May 09,.

  • Introducing Cerecor (NASDAQ:CERC), A Stock That Climbed 42% In The Last Three Years
    Simply Wall St.2 months ago

    Introducing Cerecor (NASDAQ:CERC), A Stock That Climbed 42% In The Last Three Years

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Vanguard founder Jack Bogle helped spearhead the low-cost index fund, putting average returns w...

  • GlobeNewswire2 months ago

    Cerecor Announces Positive Phase I Safety Data for CERC-801 in Healthy Volunteers

    ROCKVILLE, Md., April 29, 2019 -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for.

  • Zacks Small Cap Research2 months ago

    CERC: Positive Results for Phase 1 Trial of CERC-301…

    The Phase 1 trial is a double blind, randomized, placebo controlled trial with a target enrollment of 20 Parkinson’s patients with nOH. Each patient will have five visits in which they will receive four single escalating doses of drug (8, 12, 16, or 20 mg) or placebo.

  • ACCESSWIRE2 months ago

    Cerecor Announces Positive Interim Results of CERC-301 in the Treatment of Neurogenic Orthostatic Hypotension (nOH)

    ROCKVILLE, MD / ACCESSWIRE / April 15, 2019 / Cerecor Inc. (CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare and orphan diseases in pediatrics and neurology, today announced positive interim results from the Phase I study of CERC-301, an NMDA receptor antagonist, being developed for the treatment of symptomatic neurogenic orthostatic hypotension (nOH) in Parkinson's Disease. CERC-301 is an orally available, NR2B-specific, NMDA receptor antagonist being developed for the treatment of symptomatic neurogenic orthostatic hypotension (nOH).

  • ACCESSWIRE2 months ago

    Cerecor Announces Leadership Changes

    Dr. Simon Pedder, Ph.D. has been appointed Executive Chairman of the Board. As well, Patrick Crutcher has been promoted to Chief Strategy Officer. Peter Greenleaf will transition from the CEO role but remain on the Board of Directors, including providing strategic assistance during the transition.

  • Zacks Small Cap Research3 months ago

    CERC: Multiple Data Readouts in 2019; Commercial Unit Continues Growth…

    Cerecor, Inc. (CERC) is a fully integrated biopharmaceutical company with commercial operations intended to support the development of a pipeline of therapies targeting neurology, pediatric, and orphan indications. The neurology pipeline is led by CERC-301, which is currently in a Phase 1 clinical trial in patients with neurogenic orthostatic hypotenstion (nOH). Cerecor is currently conducting a Phase 1 clinical trial of its lead neurology candidate CERC-301 for the treatment of nOH associated with Parkinson’s disease and other neurodegenerative diseases.

  • ACCESSWIRE3 months ago

    Cerecor Reports Fourth Quarter and Full Year 2018 Results

    -Significant Advancement in Pipeline and Regulatory Milestones -Meets Increased 2018 Revenue Guidance -Announces Net Revenue Guidance of $20-22 Million for 2019 ROCKVILLE, MD / ACCESSWIRE / March 18, 2019 ...

  • ACCESSWIRE4 months ago

    Cerecor Increases Previously Announced Bought Deal of Common Stock to $10 Million

    ROCKVILLE, MARYLAND / ACCESSWIRE / March 6, 2019 / Cerecor Inc. (CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare and orphan diseases in pediatrics and neurology, announced today that, due to demand, the underwriter has agreed to increase the size of the previously announced offering and purchase on a firm commitment basis 1,818,182 shares of common stock of the Company, at a price to the public of $5.50 per share (the "Public Price"). The Company also has granted to the underwriter a 45-day option to purchase up to an additional 272,727 shares of common stock at the Public Price.

  • ACCESSWIRE4 months ago

    Cerecor Announces $8 Million Bought Deal Offering

    ROCKVILLE MD / ACCESSWIRE / March 5, 2019 / Cerecor Inc. (CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare and orphan diseases in pediatrics and neurology, announced today that it has entered into an underwriting agreement with H.C. Wainwright & Co., LLC under which the underwriter has agreed to purchase on a firm commitment basis a minimum of 1,454,546 shares of common stock of the Company, at a price to the public of $5.50 per share (the "Public Price"). H.C. Wainwright & Co. is acting as the sole book-running manager for the offering. The Company also has granted to the underwriter a 45-day option to purchase up to an additional 218,181 shares of common stock at the Public Price.

  • Do Insiders Own Lots Of Shares In Cerecor Inc. (NASDAQ:CERC)?
    Simply Wall St.4 months ago

    Do Insiders Own Lots Of Shares In Cerecor Inc. (NASDAQ:CERC)?

    Want to participate in a short research study? Help shape the future of investing tools and receive a $20 prize! Every investor in Cerecor Inc. (NASDAQ:CERC) should be aware ofRead More...

  • GlobeNewswire4 months ago

    Cerecor Receives Fast Track Designation from FDA for CERC-801 for the Treatment of PGM1 Deficiency

    Cerecor Inc. (CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare and orphan diseases in pediatrics and neurology, announced today that the U.S. Food and Drug Administration (FDA) has designated Fast Track Designation for CERC-801, an ultra-pure, oral formulation of D-galactose currently in development for the treatment of Phosphoglucomutase 1 (PGM1) deficiency, also known as PGM1-CDG. “We believe that receiving Fast Track designation for CERC-801 reinforces the high unmet need that currently exists for this ultra-rare condition affecting children with Congenital Disorders of Glycosylation,” said Peter Greenleaf, Chief Executive Officer of Cerecor.

  • GlobeNewswire4 months ago

    Cerecor Announces CERC-301 Granted U.S. Patent

    Cerecor Inc. (CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments in rare and orphan diseases in pediatrics and neurology, announced that the U.S. Patent and Trademark Office issued U.S. Patent No. 10,202,363 ("the ‘363 patent") on Feb. 12, 2019, which is directed to CERC‑301, an oral, NR2B-specific, NMDA receptor antagonist. CERC-301 is a selective NR2B-specific NMDA receptor antagonist with a unique mechanism of action tested in 375 subjects to date. CERC-301 is being developed for the treatment of Neurogenic Orthostatic Hypotension (nOH) associated with neurodegenerative diseases such as Parkinson's Disease, Multiple Systems Atrophy and Pure Autonomic Failure.

  • GlobeNewswire5 months ago

    Cerecor Announces U.S. Headquarters Move Into Pharmaceutical Corridor of Rockville, Maryland

    Cerecor Inc. (CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments in rare and orphan diseases in pediatrics and neurology, announced today that it has moved its U.S. Corporate Offices to 540 Gaither Road Suite 400 located in Rockville, Maryland.  The company had previously been based in Baltimore, Maryland. 2019 is poised to be a significant year for Cerecor.  Numerous filings are planned with the FDA around the CERC-800 programs for Congenital Disorders of Glycosylation.  There is an expected read-out of the Phase I proof of concept trial in neurogenic Orthostatic Hypotension (nOH) with CERC-301 an NMDA NR2B receptor antagonist.  We expect our commercial capabilities to continue to improve with our Pediatric Franchise.  Our commercial sales serves as a source of capability build for future assets and partial funding to our clinical pipeline and operations.

  • GlobeNewswire5 months ago

    FDA Accepts IND Application for Cerecor’s Investigational Drug CERC-801 for the treatment of PGM1 Deficiency

    Cerecor Inc. (CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare and orphan diseases in pediatrics and neurology, announced today that the FDA has accepted its Investigational New Drug (IND) application for CERC-801, an ultra-pure, oral formulation of D-galactose currently in development for the treatment of Phosphoglucomutase 1 (PGM1) deficiency, also known as PGM1-CDG. The clinical development program for CERC-801 will commence with a Phase 1 study in healthy volunteers.

  • GlobeNewswire5 months ago

    FDA Grants Cerecor’s Three Substrate Replacement Therapies Orphan Drug Designation

    Cerecor Inc. (CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of therapies for rare and orphan diseases in pediatrics and neurology, announced today that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designations (ODD) to Cerecor’s three substrate replacement therapies for Congenital Disorders of Glycosylation (CDGs). Each indication is an ultra-rare CDG estimated to have fewer than 1,000 patients in the United States.

  • GlobeNewswire6 months ago

    Antares Pharma Announces the Appointment of Peter S. Greenleaf to Company’s Board of Directors

    Antares Pharma, Inc. (ATRS) today announced the appointment of Peter S. Greenleaf to the Company’s Board of Directors.  Mr. Greenleaf has over 20 years of biopharmaceutical experience, and currently serves as the Chief Executive Officer of Cerecor Inc. (CERC), a biopharmaceutical company focused on neurological and pediatric disorders.  He is also Chairman of the Board at BioDelivery Sciences (BDSI), a specialty pharmaceutical company focused on pain management and addiction medicine.

  • Zacks Small Cap Research7 months ago

    CERC: Unveils Rare Pediatric Disease Programs…

    On October 31, 2018, Cerecor, Inc. (CERC) announced the submission of three Orphan Drug Designation (ODD) requests for three of the development products acquired from the purchase of Ichorion Therapeutics, Inc. Each of them is being developed for the treatment of ultrarare metabolic disorders known as Inborn Errors of Metabolism (IEM). CERC-801 (D-galactose): This is being developed for the treatment of Phosphoglucomutase 1 (PGM1) deficiency, a recently characterized congenital disorder of glycosylation (CDG). The multisystem deficiencies are a result of a lack of protein glycosylation, which is dependent upon the important metabolic intermediate glucose-1-phosphate.

  • What Kind Of Share Price Volatility Should You Expect For Cerecor Inc (NASDAQ:CERC)?
    Simply Wall St.7 months ago

    What Kind Of Share Price Volatility Should You Expect For Cerecor Inc (NASDAQ:CERC)?

    If you own shares in Cerecor Inc (NASDAQ:CERC) then it’s worth thinking about how it contributes to the volatility of your portfolio, overall. In finance, Beta is a measure of Read More...

  • GlobeNewswire7 months ago

    Analysis: Positioning to Benefit within KemPharm, Bellerophon Therapeutics, Exela Technologies, Intec Pharma, Cerecor, and Chiasma — Research Highlights Growth, Revenue, and Consolidated Results

    NEW YORK, Nov. 21, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • GlobeNewswire7 months ago

    Cerecor Reports Third Quarter 2018 Results

    BALTIMORE, Nov. 13, 2018 -- Cerecor Inc. (“Cerecor” or the “Company”) (NASDAQ: CERC), a fully integrated biopharmaceutical company with commercial operations and research and.

  • GlobeNewswire8 months ago

    Cerecor Announces Submission of Three Orphan Drug Designation Requests for Substrate Replacement Therapies to treat Congenital Disorders of Glycosylation

    Cerecor Inc. (CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare and orphan diseases in pediatrics and neurology, announced today that it has submitted to the U.S. Food and Drug Administration (FDA) three Orphan Drug Designation (ODD) Requests for substrate replacement therapies to treat ultra-rare inherited metabolic disorders known as Congenital Disorders of Glycosylation (CDGs). Each indication is an ultra-rare CDG estimated to have less than 1,000 patients in the United States.